University of Tokyo Researcher Has Provided New Data on Chronic Kidney Disease (Cost-Effectiveness of Empagliflozin in Chronic Kidney Disease with or without Albuminuria).

A recent study conducted by researchers at the University of Tokyo examined the cost-effectiveness of using empagliflozin in the treatment of chronic kidney disease (CKD) with or without albuminuria. The study found that empagliflozin is cost-effective for CKD patients with an urine albumin-to-creatinine ratio of 30 mg/g or more, but not for those with a ratio below 30 mg/g. The addition of empagliflozin to standard CKD treatment was deemed cost-effective for patients with albuminuria in the Japanese healthcare system. [Extracted from the article]